The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers.
Main text
Metastasis accounts for 90 percent of cancer deaths. We developed a mouse model of welldefined multistage tumorigenesis: RIP-Tag; RIP-tva to identify metastatic factors [1] . We identified that the receptor for hyaluronic acid (HA)-mediated motility, isoform B (RHAMM B ), significantly promotes liver metastasis of pancreatic neuroendocrine tumors (PNET) in RIP-Tag;
RIP-tva mouse models [2] . Expression of RHAMM is restricted in normal adult tissues, but is upregulated in cancers [3, 4] . Increased production of glycosaminoglycan, HA, is correlated with increased migration and invasion in aggressive cancers [5] . CD44 and RHAMM are two major HA receptors. 
RHAMM B , but not RHAMM A , is upregulated in human PNET liver metastases
To investigate RHAMM expression in human PNETs, a tissue microarray consisting of 83
PNETs was immunostained for RHAMM. RHAMM was not detectable in the normal pancreas, while 54 of 83 (65%) PNETs exhibited cytoplasmic staining using an antibody that recognizes common region in RHAMM isoforms (Fig. 1B) . Because isoform-specific RHAMM antibodies
were not available, we investigated the mRNA levels of RHAMM A and RHAMM B by performing significantly higher than RHAMM A in both primary and metastatic PNETs, suggesting that RHAMM B was the predominant isoform naturally expressed in PNETs. Although RHAMM A levels in primary tumors were significantly higher than those in normal islets (p = 0.0002),
RHAMM
A levels in metastatic tumors were not significantly higher than those in normal islets (p = 0.8928). The mRNAs of RHAMM A and RHAMM B were readily detectable in additional primary PNETs and metastases by RT-qPCR using isoform-specific primers ( Fig. S1A-B) .
We compared metastatic potential of RHAMM A to RHAMM B in RIP-Tag; RIP-tva models of spontaneous metastasis and tail vein assays [1, 2] . In contrast to RHAMM B , RHAMM A did not promote spontaneous metastasis (Table S1 ). Then, we generated N134 cells overexpressing (Fig. 3A) . Survival analysis showed that high RHAMM levels were correlated with a worse outcome (Fig. 3B) . Furthermore, patients with high RHAMM B had
inferior survival compared to those with high RHAMM A (Fig. 3C-D We investigated whether a constitutively active form of EGFR, EGFR*, is sufficient to recapitulate RHAMM B activity in metastasis. Five of the 8 RIP-Tag; RIP-tva mice receiving RCASBP-EGFR* developed pancreatic lymph node metastases (62.5%) and 2 developed liver metastases (25%) ( Table S1 ). We generated N134 cells overexpressing EGFR* (N134-EGFR*)
for experimental metastasis (Fig. 3G ). While no metastasis was found in mice receiving control N134-Luciferase after 6 weeks, an average of 6 liver macrometastases was detected in mice receiving N134-EGFR* (Fig. 3H ). Although EGFR* promotes liver metastasis of PNETs in both spontaneous and experimental metastasis mouse models, the degree of metastasis is less than that of RHAMM B (Table S1 and Fig. 3H ). Therefore, these EGFR knockdown and EGFR* overexpression data suggest that activation of EGFR contributes to RHAMM B -induced PNET Two-tailed Mann-Whitney U test was used to compare differences between two groups selected.
P values < 0.05 were considered as statistically significant.
Quantitative real-time reverse transcription PCR (RT-qPCR)
Messenger RNA (mRNA) was isolated from human PanNET specimens or cells grown on 6-cm or 10-cm plates using RNeasy mini kit (Qiagen) containing gDNA eliminator spin columns. The cDNA was generated using SuperScript III First-strand synthesis system with random hexamers 
Cloning of RCASBP and retroviral vectors
RCASBP is a replication-competent avian leucosis virus with a splice acceptor and the Bryan-RSV pol gene. RCASBP-RHAMM B [2] and RCASBP-EGFR* [13] have been described. Lentiviruses harboring shRNA were generated using 293T cells as described previously ( http://www.broadinstitute.org/rnai/public/resources/protocols).
RCASBP-RHAMM

Cell culture and Western blot
Generation of N134 and BON1-TGL cell lines has been described [1, 14] . Human pancreatic were cultured in DMEM supplemented with 0.5 µg/ml puromycin, 10% FBS, 6 mM L-glutamine, and penicillin/streptomycin. N134 cells overexpressing cDNAs were generated as described [15] . N134 cells overexpressing shRNAand BON1-TGL overexpressing shRNA were cultured in medium supplemented with 0.4 µg/ml puromycin and 0.5 µg/ml puromycin, respectively.
For Western blot analysis, cell extracts were loaded into mini-protean 4-15% pre-cast gels (BioRad). Protein was immobilized onto nitrocellulose membrane, 0.45 µm pore size (Bio-Rad).
Blots were blocked for one hour with 3% (weight/volume) bovine serum albumin (Fisher Scientific) and incubated overnight at 4° C with a rabbit monoclonal antibody to RHAMM
[EPR4055] antibody at 1:1,000 dilution (Abcam, ab108339). The next day blots were washed 4 times for 10 minutes with TBST and incubated for one hour at room temperature with an antirabbit secondary antibody at 1:5,000 dilution. Bands were detected with enhanced chemiluminescence.
Animal experiments
Generation of RIP-Tag; RIP-tva mice has been described [1] and detailed protocols for somatic delivery of the RCASBP viruses has been described [15] . Immunodeficient mice, NOD/scidIL2Rgc knockout (NSG), were generated by the Jackson Laboratory. This study was carried out 
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